NJ-MIPI-ALLIANCE
8.10.2019 15:05:12 CEST | Business Wire | Press release
The MIPI Alliance , an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced key advancements and activities designed to enhance advanced driver assistance systems (ADAS), autonomous driving systems (ADS) and other automotive applications.
Trends such as the proliferation of camera, display, radar, lidar and other sensors are creating growing demand for high-performance wired interfaces in vehicles. While drawing on its existing specifications for mobile devices, MIPI is developing and enhancing automotive specifications to meet the stringent requirements of automotive OEMs, Tier 1 suppliers, SoC designers and other industry providers in areas such as reliability, functional safety and low electromagnetic interference (EMI).
New automotive white paper
In a white paper published today, “MIPI Alliance: Driving the Wires of Automotive,” MIPI lays out how it is leveraging its current specifications for automotive applications and developing enhancements and new specifications for this sector. Download it here .
The white paper includes an in-depth look at the upcoming MIPI A-PHY specification and its key technical advantages. Development work is well underway on the MIPI A-PHY v1.0 physical layer specification, which will provide the automotive industry with a unified in-vehicle connectivity standard that meets the industry’s need for high speed, low latency, functional safety, lightweight wiring, low power consumption and the desired economies of scale.
A-PHY support for broadest spectrum of speed needs
A-PHY is being developed as an asymmetric data link in a point-to-point topology with high-speed unidirectional data, embedded bidirectional control data and optional power delivery over a single cable. It will support both coaxial cables up to 15 meters and shielded differential pair (SDP) cables, each with up to four inline connectors. A key application of A-PHY is to directly and efficiently carry the near-ubiquitous MIPI Camera Serial Interface-2 (MIPI CSI-2 ) and MIPI Display Serial Interface-2 (MIPI DSI-2 ) protocols between components anywhere in a vehicle, as well as other interface types. These protocols currently use the short-reach MIPI D-PHY and MIPI C-PHY physical layers and require a “bridge” to a proprietary long-reach PHY to connect widely dispersed systems. A-PHY will offer a single long-reach physical layer so designers can use the same long-reach bridge transport technology in all cases. Later, cameras, displays and SoCs will natively support A-PHY, eliminating the need for bridge chips altogether.
MIPI A-PHY is being developed on two profiles to support speeds of 2-16 Gbps, with a roadmap to 24-48 Gbps and beyond, to suit a broad spectrum of use cases and design needs. Profile 1, for lower-speed applications, is expected to deliver up to about 8 Gbps over 15 meters and offer a lowest-cost, low-complexity solution for simple implementation and shorter time to market. Profile 2 will support all A-PHY speeds and provide a pathway to higher speeds for applications that require them. The two profiles will interoperate to ensure compatibility, as well as gradual system scale-up. When complete, A-PHY will serve a broad spectrum of longer-reach, high-speed connectivity needs, including IoT and industrial applications.
Next generation of automotive electronics specifications
MIPI A-PHY v1.0 specification work is expected to be completed by the end of 2019, with the specification available in early 2020. Meanwhile, MIPI is now identifying requirements for A-PHY v2.0, and OEMs, Tier 1 suppliers and others in the automotive ecosystem are invited to join MIPI to contribute to this important work. It’s anticipated that the first vehicles using A-PHY components will be in production in 2024.
MIPI is also updating other specifications to meet the requirements of increasingly advanced vehicles and to help system designers, developers and manufacturers bring new technologies and features to market more quickly and at lower costs. For example, MIPI CSI-2 v3.0 was released recently—a significant update of the primary interface used to connect camera sensors to application processors. Enhancements include RAW-24, for representing individual image pixels with greater precision, which could help autonomous vehicles to more accurately identify obstacles and hazards.
“MIPI Alliance is involved in automotive standards-making at an exciting time in the evolution of the industry,” said Joel Huloux, chairman of MIPI Alliance. “Similar to the impacts of standardization in the mobile industry, so too will MIPI specifications significantly shape the automotive industry. The activities underway and the active involvement of our members at key industry events and other forums demonstrate how MIPI is helping to define the next generation of automotive electronics interfaces.”
Additional opportunities and resources
Continuing its active involvement in the automotive space, MIPI has more related activities coming up.
- Join us at MIPI DevCon Taipei for sessions on MIPI in Automotive topics.
- Look for a series of webinars coming this fall, beginning with “MIPI in Automotive," followed by more focused presentations on MIPI specifications for camera, display, storage and other automotive application areas.
- Check our events page for opportunities to meet with MIPI representatives at upcoming automotive events.
To discover more about MIPI Alliance, subscribe to its blog and connect with its social networks by following MIPI on Twitter , LinkedIn and Facebook .
About MIPI Alliance
MIPI Alliance (MIPI) develops interface specifications for mobile and mobile-influenced industries. There is at least one MIPI specification in every smartphone manufactured today. Founded in 2003, the organization has over 300 member companies worldwide and 14 active working groups delivering specifications within the mobile ecosystem. Members of the organization include handset manufacturers, device OEMs, software providers, semiconductor companies, application processor developers, IP tool providers, automotive OEMs and Tier 1 suppliers, and test and test equipment companies, as well as camera, tablet and laptop manufacturers. For more information, please visit www.mipi.org .
MIPI® is a registered trademark owned by MIPI Alliance. MIPI CSI-2℠, MIPI DSI-2℠, MIPI A-PHY℠, MIPI D-PHY℠ and MIPI C-PHY℠ are service marks of MIPI Alliance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
